-+ 0.00%
-+ 0.00%
-+ 0.00%

Physiomics Wins Contract to Support Numab's Antibody Development

MT Newswires·12/11/2025 07:02:07
Listen to the news
07:02 AM EST, 12/11/2025 (MT Newswires) -- Physiomics (PYC.L) secured a contract from Numab Therapeutics to support the long-standing client's pre-clinical development of a multi-specific antibody. The British data science group will develop a mechanistic pharmacokinetics and pharmacodynamics model to understand the drug's behavior and inform dosing for preclinical and clinical studies, according to a Thursday release. Project delivery is expected in fiscal 2026.